Viking Therapeutics Inc (NASDAQ:VKTX) Reports Q2 2025 Earnings: Wider Loss Than Expected, Shares Dip in After-Hours Trading
Viking Therapeutics Inc, a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, reported its second-quarter 2025 financial results after market close on July 23, 2025. The company posted a wider-than-expected loss, leading to a negative reaction in after-hours trading.
Key Financial Highlights
- Revenue: Reported revenue for Q2 2025 was $0.0, in line with analyst estimates.
- Earnings Per Share (EPS): The company reported a loss of $0.58 per share, missing the consensus estimate of -$0.4553 by a significant margin.
- Market Reaction: Following the earnings release, shares fell ~5.7% in after-hours trading, reflecting investor disappointment over the larger-than-anticipated loss.
Performance Context
Despite the post-earnings dip, Viking Therapeutics' stock has shown resilience over the past month, gaining 29.1%. However, short-term performance remains muted, with a 0.06% increase over the last two weeks and a 0.05% uptick in the past week.
Analyst Estimates for Future Quarters
Looking ahead, analysts expect continued challenges in profitability:
- Q3 2025 Revenue Estimate: $0.0
- Q3 2025 EPS Estimate: -$0.5057
- Full-Year 2025 Revenue Estimate: $1.5 million (primarily from potential milestone payments or collaborations)
- Full-Year 2025 EPS Estimate: -$1.93
Given the lack of revenue generation, investor focus remains on the company’s clinical pipeline progress rather than near-term financial performance.
Corporate and Clinical Updates
While the press release did not provide explicit forward guidance, Viking Therapeutics highlighted ongoing developments in its clinical programs:
- VK2809: A Phase IIb study for non-alcoholic steatohepatitis (NASH) and fibrosis remains a key focus.
- VK0214: Development continues for X-linked adrenoleukodystrophy (X-ALD), a rare neurological disorder.
- VK2735: The dual GLP-1/GIP receptor agonist for metabolic disorders is another promising candidate in the pipeline.
The absence of revenue-generating products means the company’s valuation hinges heavily on clinical trial outcomes and potential partnerships.
Conclusion
Viking Therapeutics’ Q2 earnings miss underscores the inherent risks of investing in clinical-stage biotech firms, where financial performance is secondary to pipeline progress. The after-hours sell-off suggests investor caution, but the stock’s recent monthly gains indicate optimism around its long-term prospects.
For a deeper dive into Viking Therapeutics’ earnings history and future estimates, visit the earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research or consult a financial advisor before making any decisions.
